MS4A1 and B-cell non-Hodgkin lymphoma: To the best of our knowledge, our study is the first to compare the distribution of 89Zr-rituximab with and without a standard preload of unlabelled rituximab in patients with relapsed CD20+ B-cell lymphoma.